Stocks and Investing
Stocks and Investing
Thu, December 9, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jason Butler Maintained (ACAD) at Buy with Increased Target to $39 on, Dec 9th, 2021
Jason Butler of JMP Securities, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Increased Target from $35 to $39 on, Dec 9th, 2021.
Jason has made no other calls on ACAD in the last 4 months.
There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 4 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Salveen Richter of "Goldman Sachs" Maintained at Hold with Increased Target to $28 on, Wednesday, December 8th, 2021
- Vamil Divan of "Mizuho" Maintained at Hold with Increased Target to $26 on, Tuesday, December 7th, 2021
- Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021
- Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $28 on, Tuesday, December 7th, 2021
This is the rating of the analyst that currently disagrees with Jason
- Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $23 on, Monday, November 1st, 2021
Contributing Sources